These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8888129)

  • 1. Dyskinesias and their treatment with essential fatty acids: a review.
    Vaddadi K
    Prostaglandins Leukot Essent Fatty Acids; 1996 Aug; 55(1-2):89-94. PubMed ID: 8888129
    [No Abstract]   [Full Text] [Related]  

  • 2. Taurine treatment of dyskinesias: an attempt.
    Nyland H; Engelsen BA; Blom H
    Eur Neurol; 1989; 29(3):121-3. PubMed ID: 2525093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic use of tiapride in movement disorders].
    Mathé JF; Cler JM; Venisse JL
    Sem Hop; 1978 May; 54(13-16):517-20. PubMed ID: 211595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapies for tardive dyskinesia: part 2.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Jul; 49(7):17-20. PubMed ID: 21667885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease.
    Clifford JJ; Drago J; Natoli AL; Wong JY; Kinsella A; Waddington JL; Vaddadi KS
    Neuroscience; 2002; 109(1):81-8. PubMed ID: 11784701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium therapy in Huntington's chorea and tardive dyskinesia.
    Dalén P
    Lancet; 1973 Jan; 1(7794):107-8. PubMed ID: 4118636
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H; Sabouraud O
    Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemiballismus.
    N Engl J Med; 1977 Mar; 296(13):758. PubMed ID: 138797
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes.
    Fog R; Pakkenberg H
    Acta Neurol Scand; 1970; 46(2):249-51. PubMed ID: 4246984
    [No Abstract]   [Full Text] [Related]  

  • 11. Deanol in the management of involuntary movement disorders: a review.
    Casey DE
    Dis Nerv Syst; 1977 Dec; 38(12 Pt 2):7-15. PubMed ID: 145359
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs affecting movement disorders.
    Campanella G; Roy M; Barbeau A
    Annu Rev Pharmacol Toxicol; 1987; 27():113-36. PubMed ID: 2953302
    [No Abstract]   [Full Text] [Related]  

  • 13. [Action of sulpiride on abnormal movements].
    Lille Med; 1972 Jan; 17():Suppl 1:14-8. PubMed ID: 4260326
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of haloperidol in the treatment of extrapyramidal compulsive movement].
    Kivalo E; Weckman N
    Nervenarzt; 1970 Nov; 41(11):567-9. PubMed ID: 4249744
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained relief of hemiballismus.
    Rowlands IP
    Br Med J; 1972 Apr; 2(5808):296. PubMed ID: 4259962
    [No Abstract]   [Full Text] [Related]  

  • 16. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia.
    Goety CG; Tanner CM; Cohen JA; Thelen JA; Carroll VS; Klawans HL; Fariello RG
    Mov Disord; 1990; 5(3):263-5. PubMed ID: 2143808
    [No Abstract]   [Full Text] [Related]  

  • 17. Tetrabenazine and movement disorders.
    Asher SW; Aminoff MJ
    Neurology; 1981 Aug; 31(8):1051-4. PubMed ID: 6455607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lecithin in neurologic disorders.
    Barbeau A
    N Engl J Med; 1978 Jul; 299(4):200-1. PubMed ID: 149251
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
    Frattola L; Albizzati MG; Bassi S; Spano PF; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():381-6. PubMed ID: 6446848
    [No Abstract]   [Full Text] [Related]  

  • 20. Lingual-facial-buccal movements in the elderly. I. Pathophysiology and treatment.
    Weiner WJ; Klawans HL
    J Am Geriatr Soc; 1973 Jul; 21(7):314-7. PubMed ID: 4268288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.